New Study Shows Omicron Variant More Resistant to Vaccines, but Appears to Cause Less Severe Illness

We are getting more information on the Omicron variant from the first large real-world study in South Africa and see protection from hospitalization fall to 70% and against infection fall to 33%. This study pitted the new variant against two shots of Pfizer, which has been widely used in the area. Denise Roland, healthcare reporter at the WSJ, joins us for what we are seeing from Omicron, more transmissible and so far, milder infections. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com